Literature DB >> 19381634

Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment.

H Morbach1, P Richl, S Stojanov, P Lohse, Hermann J Girschick.   

Abstract

The objectives of this study are autoinflammatory syndromes which are usually characterized by repeated attacks of fever, especially in children. The presentation of these diseases, however, varies between entities and between patients of a particular syndrome. We report a 16-year-old female patient, who suffered from periodic erythema and myositis/fasciitis. She experienced at least nine attacks of dermatitis and myositis, while no fever episodes were noted over a 3-year period. A delay of puberty with amenorrhea and a short stature were also present. Laboratory investigations consistently showed markedly increased inflammatory parameters (especially a high serum amyloid A) and dysproteinemia. Because the patient′s mother complained about chronic and periodic abdominal pain with also persistently elevated inflammatory parameters, the differential diagnosis included hereditary disorders resulting in chronic inflammation. The diagnosis of an inherited tumor necrosis factor receptor (TNFR) 1-associated periodic syndrome (TRAPS) was confirmed by genetic analyses. Long-term anti-inflammatory treatment with etanercept resulted in a significant clinical improvement and reduction of the inflammatory parameters ESR, CRP, interleukin-6, TNF-α, and soluble TNF-α receptor 1, but not of interleukin-12. Monitoring of the cytokine profile suggested partial effectiveness of etanercept in the treatment of TRAPS. Hereditary fever syndromes have to be considered in case of chronic unexplained inflammation even if fever is no presenting symptom.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381634     DOI: 10.1007/s00296-009-0937-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

Authors:  M F McDermott; I Aksentijevich; J Galon; E M McDermott; B W Ogunkolade; M Centola; E Mansfield; M Gadina; L Karenko; T Pettersson; J McCarthy; D M Frucht; M Aringer; Y Torosyan; A M Teppo; M Wilson; H M Karaarslan; Y Wan; I Todd; G Wood; R Schlimgen; T R Kumarajeewa; S M Cooper; J P Vella; C I Amos; J Mulley; K A Quane; M G Molloy; A Ranki; R J Powell; G A Hitman; J J O'Shea; D L Kastner
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

2.  Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.

Authors:  E Drewe; M L Huggins; A G Morgan; M J D Cassidy; R J Powell
Journal:  Rheumatology (Oxford)       Date:  2004-08-17       Impact factor: 7.580

3.  Periodic fever due to a novel TNFRSF1A mutation in a heterozygous Chinese carrier of MEFV E148Q.

Authors:  S Stojanov; P Lohse; M F McDermott; E D Renner; A Kéry; R Mirakian; L J Hammond; E Aganna; F Hoffmann; S Zellerer; B H Belohradsky
Journal:  Rheumatology (Oxford)       Date:  2004-04       Impact factor: 7.580

4.  Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.

Authors:  M L Nowlan; E Drewe; H Bulsara; N Esposito; R A Robins; P J Tighe; R J Powell; I Todd
Journal:  Rheumatology (Oxford)       Date:  2005-11-15       Impact factor: 7.580

5.  Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function.

Authors:  Susana L Rebelo; Susan E Bainbridge; Mohammad R Amel-Kashipaz; Paul M Radford; Richard J Powell; Ian Todd; Patrick J Tighe
Journal:  Arthritis Rheum       Date:  2006-08

Review 6.  Amyloidosis and auto-inflammatory syndromes.

Authors:  Gilles Grateau; Isabelle Jéru; Saad Rouaghe; Cécile Cazeneuve; Nathalie Ravet; Philippe Duquesnoy; Laurence Cuisset; Catherine Dodé; Marc Delpech; Serge Amselem
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-02

7.  Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients.

Authors:  E Drewe; E M McDermott; P T Powell; J D Isaacs; R J Powell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

Review 8.  TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis.

Authors:  Catherine Dodé; Laurence Cuisset; Marc Delpech; Gilles Grateau
Journal:  J Nephrol       Date:  2003 May-Jun       Impact factor: 3.902

9.  The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Catherine Dodé; Marc André; Thierry Bienvenu; Pierre Hausfater; Christophe Pêcheux; Jacques Bienvenu; Jean-Claude Lecron; Philippe Reinert; Daniel Cattan; Jean-Charles Piette; Marie-France Szajnert; Marc Delpech; Gilles Grateau
Journal:  Arthritis Rheum       Date:  2002-08

Review 10.  The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.

Authors:  Keith M Hull; Elizabeth Drewe; Ivona Aksentijevich; Harjot K Singh; Kondi Wong; Elizabeth M McDermott; Jane Dean; Richard J Powell; Daniel L Kastner
Journal:  Medicine (Baltimore)       Date:  2002-09       Impact factor: 1.889

View more
  4 in total

Review 1.  Tumor necrosis factor-associated periodic syndrome in adults.

Authors:  Sharika Gopakumar Menon; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-09-23       Impact factor: 2.631

2.  Variable intrafamilial expressivity of the rare tumor necrosis factor-receptor associated periodic syndrome-associated mutation I170N that affects the TNFR1A cleavage site.

Authors:  Petra Lehmann; Bernd Salzberger; Peter Haerle; Ivona Aksentijevich; Daniel Kastner; Juergen Schoelmerich; Stephanie Rosenfeld; Ulf Mueller-Ladner
Journal:  Mod Rheumatol       Date:  2010-02-19       Impact factor: 3.023

Review 3.  Monogenic autoinflammatory diseases: concept and clinical manifestations.

Authors:  Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Clin Immunol       Date:  2013-04-09       Impact factor: 3.969

4.  Pediatric psoriasis: an update.

Authors:  Nanette B Silverberg
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.